Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans

被引:9
|
作者
Dorneles, Jessica [1 ]
Madruga, Andriele Bonemann [1 ]
Pinto Seixas Neto, Amilton Clair [1 ]
Rizzi, Caroline [1 ]
Bettin, Everton Burlamarque [1 ]
Hecktheuer, Amanda Silva [1 ]
de Castro, Clarissa Caetano [2 ]
Fernandes, Cristina Gevehr [2 ]
Oliveira, Thais Larre [1 ]
Dellagostin, Odir Antonio [1 ]
机构
[1] Univ Fed Pelotas, Ctr Desenvolvimento Tecnol, Programa Posgrad Biotecnol, Pelotas, RS, Brazil
[2] Univ Fed Pelotas, Dept Patol Anim, Programa Posgrad Vet, Pelotas, RS, Brazil
关键词
Vectored vaccine; BioBricks; Chimera; LipL32; LigAni; LemA; VACCINE;
D O I
10.1016/j.vaccine.2020.10.086
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Leptospirosis is a zoonotic disease worldwide and caused by the pathogenic spirochetes of the genus Leptospira. Bacterins make up the vaccines used against leptospirosis, but they only succeed in providing short-term and serovar-specific protection. The use of Mycobacterium bovis BCG as a live vaccine vector expressing leptospiral antigens is a promising alternative, particularly due to its adjuvant properties. Four distinct portions P-1 (lipL32), P-2 (ligAni), P3 (lemA: ligAni) and P-4 (lipL32:lemA) of a recombinant chimera composed of the lipL32, lemA and ligANI genes from Leptospira interrogans were cloned individually according to the BioBricks (R) strategy in the plasmid pUP500/PpAN. These constructs were individually transformed into a BCG Pasteur strain, and protein expression was detected by Western blot. For vaccination, 5 groups of 10 Golden Syrian hamsters were used, aged 4-6 weeks - group 1, rBCG (LipL32); group 2, rBCG (LigAni); group 3, rBCG (LemA:LigAni); group 4, (LipL32:LemA); group 5, wild-type BCG Pasteur (negative control). Two doses containing 10(6) CFU of rBCG were administered subcutaneously, the challenge was performed with 5 x LD50 of Leptospira interrogans serovar Copenhageni L1-130, and the animals were observed for a 30-day period until the endpoint was reached. Humoral immunity was assessed via indirect ELISA, while renal colonisation was assessed by culture and quantitative real-time PCR. All vaccinated groups were protected against lethal challenge and renal colonisation, in comparison with negative control group (P < 0.05). Recombinant vaccines were not effective at inducing significant humoral immunity, which suggests the induction of cellular immunity - a characteristic of M. bovis BCG. In conclusion, all formulations provide 100% significant protection against leptospirosis in hamsters with no renal colonisation. The use of rBCG as a vaccine vector represents a promising alternative for the control of animal leptospirosis, allowing for protection against clinical signs of leptospirosis and renal colonisation. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:8136 / 8144
页数:9
相关论文
共 50 条
  • [21] Oral vaccination against bovine tuberculosis with Mycobacterium bovis BCG
    Cross, Martin L.
    Aldwell, Frank
    EXPERT REVIEW OF VACCINES, 2007, 6 (03) : 323 - 331
  • [22] Isolation of Leptospira interrogans serovar Hardjoprajitno from a calf with clinical leptospirosis in Chile
    Salgado, Miguel
    Otto, Barbara
    Moroni, Manuel
    Sandoval, Errol
    Reinhardt, German
    Boqvist, Sofia
    Encina, Carolina
    Munoz-Zanzi, Claudia
    BMC VETERINARY RESEARCH, 2015, 11
  • [23] Whole-genome analysis of Leptospira interrogans to identify potential vaccine candidates against leptospirosis
    Gamberini, M
    Gómez, RM
    Atzingen, MV
    Martins, EAL
    Vasconcellos, SA
    Romero, EC
    Leite, LCC
    Ho, PL
    Nascimento, ALTO
    FEMS MICROBIOLOGY LETTERS, 2005, 244 (02) : 305 - 313
  • [24] DURATION OF PROTECTION AGAINST TUBERCULOSIS CONFERRED BY BCG VACCINATION IN INFANCY
    PACKE, GE
    INNES, JA
    ARCHIVES OF DISEASE IN CHILDHOOD, 1989, 64 (04) : 634 - 635
  • [25] PURIFICATION AND CHARACTERIZATION OF 2 PROTEIN ANTIGENS FROM THE HETEROGENOUS BCG85 COMPLEX IN MYCOBACTERIUM-BOVIS BCG
    WIKER, HG
    HARBOE, M
    LEA, TE
    INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1986, 81 (04): : 298 - 306
  • [26] PROTECTION AGAINST GUINEA-PIG HEPATOMAS BY PRETREATMENT WITH SUBCELLULAR FRACTIONS OF MYCOBACTERIUM-BOVIS (BCG)
    MINDEN, P
    WAINBERG, M
    WEISS, DW
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 52 (05) : 1643 - 1645
  • [27] IMMUNOLOGICAL RESPONSES AND PROTECTION AGAINST MYCOBACTERIUM-BOVIS IN CALVES VACCINATED WITH A LOW-DOSE OF BCG
    BUDDLE, BM
    DELISLE, GW
    PFEFFER, A
    ALDWELL, FE
    VACCINE, 1995, 13 (12) : 1123 - 1130
  • [28] Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG
    Fátima Reyes
    Yanely Tirado
    Alina Puig
    Reinier Borrero
    Giselle Reyes
    Sonsire Fernández
    José Luis Pérez
    Ramlah Kadir
    Caridad Zayas
    Mohd Nor Norazmi
    María E Sarmiento
    Armando Acosta
    BMC Immunology, 14
  • [29] Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis
    Vordermeier, H. Martin
    Villarreal-Ramos, Bernardo
    Cockle, Paul J.
    McAulay, Martin
    Rhodes, Shelley G.
    Thacker, Thyler
    Gilbert, Sarah C.
    McShane, Helen
    Hill, Adrian V. S.
    Xing, Zhou
    Hewinson, R. Glyn
    INFECTION AND IMMUNITY, 2009, 77 (08) : 3364 - 3373
  • [30] Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG
    Reyes, Fatima
    Tirado, Yanely
    Puig, Alina
    Borrero, Reinier
    Reyes, Giselle
    Fernandez, Sonsire
    Luis Perez, Jose
    Kadir, Ramlah
    Zayas, Caridad
    Norazmi, Mohd Nor
    Sarmiento, Maria E.
    Acosta, Armando
    BMC IMMUNOLOGY, 2013, 14